Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure

BACKGROUND AND OBJECTIVES: Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have a cardiovascular benefit in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Chang-Myung, Cho, Sungsoo, Jang, Ji-Yong, Kim, Hyeongseok, Chun, Sukyung, Choi, Minkyung, Park, Sangkyu, Ko, Young-Guk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Cardiology 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875592/
https://www.ncbi.nlm.nih.gov/pubmed/31456369
http://dx.doi.org/10.4070/kcj.2019.0180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875592/
https://www.ncbi.nlm.nih.gov/pubmed/31456369
http://dx.doi.org/10.4070/kcj.2019.0180

Ejemplares similares